RV001V

BIOLOGICAL2 trials

Sponsors

RhoVac APS

Conditions

Prostate CancerProstate Cancer Recurrent

Phase 1

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

CompletedNCT03199872

RhoVac APSProstate Cancer

Start: 2017-03-30End: 2019-03-29Updated: 2020-06-09

Phase 2

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Active, not recruitingNCT04114825

RhoVac APSProstate Cancer Recurrent

Start: 2019-11-19End: 2022-11-30Target: 180Updated: 2021-09-28

Related Papers

Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial

Vaccines2025-04-05

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Journal for ImmunoTherapy of Cancer2020-11-0160 citations